From Yahoo Finance: 2025-06-17 13:32:00

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is highlighted as one of the best NASDAQ stocks under $50 to buy. H.C. Wainwright analysts reaffirmed a Buy rating with a $30.00 price target, representing a 237% upside. Positive three-year data on hereditary angioedema treatment was presented at a medical meeting. A single dose of lonvoguran ziclumeran showed a remarkable 98% reduction in monthly attack rates for HAE patients.

The Phase 1 trial results for Intellia’s gene editing therapy showed sustained effectiveness over three years. Gene editing aims to create lasting changes in the genome, aligning with the treatment’s long-term impact. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a Massachusetts-based company focused on developing curative genome editing therapies in partnership with AvenCell Therapeutics, Inc.

While Intellia Therapeutics, Inc. (NTLA) presents investment potential, some believe other AI stocks offer higher upside with lower risk. Investors seeking undervalued AI stocks may benefit from a free report on the best short-term AI stock. The company’s collaboration with AvenCell Therapeutics aims to deliver innovative therapies for various diseases.



Read more at Yahoo Finance: Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential